Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00343941
Status:
COMPLETED
Last Update Posted:
2008-10-13
First Post:
2006-06-22
Brief Title:
Tucaresol As Add-On To HAART Highly Active Antiretroviral Therapy In Chronic HIV-1 Infected Adults
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase II Multicentre Randomized Double Blind Parallel Group Placebo Controlled Pilot Study of Tucaresol at Two Dosing Levels 2550 mg in HIV-1 Infected Adult Subjects With Plasma HIV-1 RNA 50 Copiesml on Stable Highly Active Antiretroviral Therapy Regimen for at Least 3 Months
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a pilot study designed to determine a dose and schedule of Tucaresol that can be administered to HIV-1 infected subjects on HAART highly active antiretroviral therapy with viral suppression without occurrence of significant adverse events and that results in significant changes in cell mediated immunity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None